The real-world safety profile of tisagenlecleucel appears to be more favourable than that reported in the JULIET study, which led to its FDA approval.
The GI Cancers Symposium revealed new therapies for specific cancer subsets and progress in chimeric antigen receptor T-cell ...
Taking a patient's immune cells and targeting their cancer with them, which is called CAR T cell therapy, is showing promise ...
Researchers with City of Hope and MSK have created a tool that uses machine learning to assess a non-Hodgkin lymphoma (NHL) ...
Cancer Center have created a tool that uses machine learning to assess a non-Hodgkin lymphoma (NHL) patient's likely response ...
Recent innovations include engineering CAR T-cells to overcome the immunosuppressive tumour microenvironment and enhancing ...
If preclinical findings were translated into clinic, they could shorten CAR-T generation lead time to one day.
Several studies have been conducted, but questions remain about where such therapies will fit into multiple myeloma treatment ...
The following is a summary of “BCMA CAR-T therapy as salvage therapy in patients with plasmablastic myeloma,” published in ...
Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) recently published two papers that advance the science ...
A second phase 1 trial plans to evaluate CER-1236, a novel chimeric antigen receptor therapy, for solid tumors.
On Tuesday, a Broadalbin man with blood cancer was the first patient to receive a groundbreaking cancer treatment at a local ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback